Revision total hip arthroplasty (rTHA) is crucial in orthopedic surgery due to the increasing need for hip replacements and patients’ longevity. The United States has surged in rTHA, expected to rise further, driven by factors like an aging population and expanding indications for primary THA. Financially, rTHA poses challenges due to higher costs and evolving reimbursement policies. Medicare significantly influences reimbursement rates and pushes for value-based models. Surgeons face reimbursement complexities and increased workload, impacting their income. Hospitals also bear financial strain with rising costs despite efforts to optimize resource utilization. Strategies like bundled payments and cost containment programs are vital. Collaboration among stakeholders is crucial to ensure sustainable operations and high-quality care for rTHA patients. Addressing these financial implications requires proactive measures and collaboration across healthcare systems.